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Abstract
Maintaining high-quality care for urological patients is a challenge during and after the Coronavirus disease 2019 (COVID-
19) pandemic. We observe an increasing volume of postponed elective visits at our tertiary care hospital, holding the risk 
for deterioration of non-emergency disease conditions. As it is unclear for how long the pandemic will last, we propose to 
implement telehealth as a solution to provide regular symptom monitoring compatible with social distancing guidelines 
during the pandemic and beyond. Telemedical assessment and prioritizing of high-risk patients for individual consults at 
outpatient services will have to be aligned with available outpatient capacity and local outbreak severity.
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Background
Initially discovered in Wuhan, the Severe Acute Respiratory 
Syndrome Corona Virus 2 (SARS-CoV-2) [1] has rapidly 
spread around the world and hence has been declared a pan-
demic by the world health organization (WHO) on March 
11, 2020 [2]. As the outbreak forced health care systems to 
reallocate medical resources to provide capacities for the 
overwhelming surge of COVID-19 patients, the majority of 
elective urological outpatient procedures at our hospital have 
been suspended and postponed.
With more than 155,000 confirmed cases and more than 
6000 reported deaths in Germany as of April 29, 2020 [3] 
the current efforts are mostly directed towards managing 
the acute situation and developing curative treatments [4] or 
vaccinations [5]. Yet, adapting and maintaining outpatient 
care is another arising challenge [6]. As the majority of uro-
logical private practices shut down during the first COVID-
19 surge, the burden of postponed elective treatments on 
our healthcare systems dramatically grows. Moreover, as 
prolonged or intermittent social distancing might be neces-
sary until as late as 2022 [7], solutions for outpatient care 
should be suitable for long-term implementation, if required.
As a large tertiary referral center, we sought to establish 
a strategy to overcome the anticipated increase in patient 
volume and provide adapted outpatient care in the post-
pandemic phase.
Methods
Anonymized patient data were obtained from digital patient 
records of all elective patients appointed for urology out-
patient visits between 16th March and 12th April. A basic 
COVID-19 risk assesses for all patients was performed in 
terms of travel history, fever, respiratory symptoms, sus-
pected or confirmed COVID-19 status, and primary health 
care referrals. In accordance with institutional guidelines, 
the institutional review board (Ethikkomission der Ludwig-
Maximilian-Universität München) has reviewed the project 
design and waived need for approval (Reference number: 
20-340). Descriptive statistics were performed, Fisher’s 
exact test and Mann–Whitney U test were applied for 
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univariate analyses of categorical variables and continuous 
variables, respectively.
Patient characteristics
Patient characteristics are summarized in Table 1. 316 
patients with non-malignant urological conditions, mainly 
by referral due to complexity or chronic reoccurrence of 
disease were scheduled for an appointment at our spe-
cialized urological outpatient clinic for the study period 
of 4 weeks. 30 patients (9.49%) were seen as scheduled 
whereas 286 (90.51%) were rescheduled (Fig. 1a). Median 
age of all patients was 64 years (IQR 51–75). 54.7% of the 
patients were classified as ASA ≤ 2, 45.3% were ASA > 2. 
The overall rate of patients with comorbidities was signifi-
cantly higher in BPH (70.58% (96/136)) than in urolithi-
asis (56.67% (34/60)) or incontinence (48.75% (39/80)). In 
Andrology rate of comorbid patients was the lowest (18.33% 
(11/60)) (each p < 0.05, respectively) (Table 1). 
Postponement of elective patients: recent 
experience and future challenges
Adapted procedures in outpatient clinics 
of a university hospital
As a reaction to COVID-19 outbreak in Munich, the Lud-
wig-Maximilian-University Hospital implemented guide-
lines to manage the upcoming challenges. In accordance 
with regulations by health care officials, immediate cessa-
tion of deferrable consultations was arranged. Appointments 
were rescheduled and only in cases of immediate urgency, 
such as urinary retention or severe infections, consultation 
in our outpatient clinic was authorized (Fig. 1a).
Unmet amount of elective patients
As COVID-19 regulations jeopardized treatment of elec-
tive patients in our urological outpatient clinic, we faced the 
postponement of 286 out of 316 elective patients (Table 1)
within 4 weeks between 16th March and 12th April. Only 
30 patients were seen as scheduled. Scaled up by con-
stantly incoming new appointment requests, the burden of 
deferred elective patients critically rises with ongoing of the 
COVID-19 pandemic—particularly, as its end and the point 
of returning to pre-pandemic routines are uncertain [7]. In a 
tertiary care setting, we expect deferred elective patients to 
reach critical burden even faster than for higher prioritized 
oncologic patients [8], such that catching up on postponed 
visits may exceed capacities many times over. As treatment 
capacities cannot be expanded beyond a certain degree and 
distribution of health resources will likely become competi-
tive, we will most likely face a supply shortfall for elective 
patients. As secondary care is mostly shut down, transfer to a 
resident urologist, as previously described for uro-oncology 
patients [6], is not an option.
COVID‑19 side effects: elective turning into urgent
Without adequate treatment, even chronic or non-emergency 
disease conditions can deteriorate and turn into acute prob-
lems. With the postponement of treatment, lower urinary 
tract symptoms (LUTS) due to benign prostate hyperplasia 
(BPH) decompensate, leading to acute urinary retention with 
an enhanced risk for renal failure and urosepsis. Likewise, 
a known urolithiasis, prone to infections or chronic urinary 
tract infections (UTI) can deteriorate with increased risk for 
severe infections and urosepsis. In tertiary care centers, the 
deferment of treatment may cause severe physical impair-
ment, as many patients have reduced physiological resil-
ience due to comorbidities and high complexity of cases. 
Conversely, in andrology, the urgency may arise from a 
certain window of opportunity for fertility assessment and 
treatment.
Preventing the overload: continuous 
reassessment and early reopening 
of outpatient services
With the burden of postponed elective patients increasing, 
we see the need for a risk and urgency adapted continuous 
reassessment of patients during the pandemic. To sustain 
high standards of medical care and simultaneously ensure 
social distancing, patients should be followed up remotely 
during the COVID-19 pandemic and beyond, if required. 
The best solution in our opinion is telehealth measures as 
regular symptom assessment to check for deterioration of the 
electively managed disease condition. We propose imple-
mentation of a simple telemedical two-step algorithm. In 
STEP 1, which substitutes scheduled appointments, patients 
should be consulted by trained physicians over the phone 
to assess the symptoms and the level of suffering, apply-
ing standardized scores. Only in case of acute deterioration, 
consultation in outpatient clinics should be authorized. For 
STEP 2, patient apps for outcome recording should be imple-
mented to provide continuous symptom control, as they have 
proven efficacy in oncology where they have already been 
established [9]. This steady reassessment allows the neces-
sary triage of elective patients. In doing so, the forthcoming 
caseload of elective patients could be controlled and miti-
gated, preventing outpatient centers to be overwhelmed. 
As major hurdles, reimbursement and regulatory issues are 
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Fig. 1   a Appointments in the 
urological outpatient clinic 
during shutdown. b Telemedical 
management of patients during 
shutdown
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perceived, but governments might be willing to adapt dur-
ing this pandemic [10]. Assisted by telemedical symptom 
assessment, triage for appointments should be based on the 
probability of deterioration, the current outpatient capacity 
and local risk for SARS-CoV-2 infections (Fig. 1b). Further-
more, we must strive for the early reopening of outpatient 
clinics as soon as the curve flattens to avoid later short cuts 
and deterioration in the medical service. As patients should 
be already virtually reassessed for potential progression of 
their diseases during the pandemic, a restart should be per-
formed following the same triaging principles. Probability of 
deterioration, time aspect in andrology and outpatient capac-
ity should be used to prioritize patients.
Experience after re‑opening of outpatient clinic
The current burden of postponed elective treatments 8 weeks 
after gradually reopening our outpatient clinic is shown in 
supplemental Fig. 1. A total 2.5% (8/316) of the patients 
were admitted due to emergencies, 41.5% (131/316) of 
the patients were rescheduled and appointed and 56.0% 
(177/316) of the postponed patients remain to be appointed 
(Suppl. Figure 1).
Conclusion
Providing a high standard of medical care for elective out-
patients is a challenge as the COVID-19 pandemic pro-
longs. The implementation of strategies to maintain sur-
veillance and care for patients with deferrable requests 
appears essential at this time to prevent undersupply in the 
post-COVID-19 era. Telehealth should play a crucial role 
to ensure safe and efficient reevaluation of patients. Partial 
reopening of outpatient clinics should be pursued as early 
as possible, taking into account patient risk and urgency 
of individual requests.
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